Morcellation Containment System Guidance Stresses Leak Detection, Prevention
Executive Summary
A new US FDA draft guidance explains what the agency wants to see in submissions for the devices, which are used to contain potentially cancerous tissue during laparoscopic surgery. Strength, permeability and leakage testing are all key considerations.
You may also be interested in...
FDA’s Power Morcellation Containment System Guidance Doc Finalized
The US FDA has finalized a guidance document that details performance assessment standards for power morcellation containment systems. The class II devices have been an object of special scrutiny since the agency learned that power morcellation could spread cancerous tissue throughout the body.
Power Morcellation Containment Devices Placed In FDA Class II
The special controls are to include biocompatibility, sterility and performance testing, as well as physician training and warning labels.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.